Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Post Exposure Prophylaxis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    95 result(s) found for: Post Exposure Prophylaxis. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2011-003799-35 Sponsor Protocol Number: RAL-PEP Start Date*: 2012-01-05
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Comparison of two antiretroviral regimens in HIV Post-exposure Prophylaxis: TDF-FTC (Truvada®) + Lopinavir/ritonavir (kaletra®) versus TDF-FTC (Truvada®) + raltegravir (Isentress®)
    Medical condition: HIV- post exposition prophylaxis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003447-21 Sponsor Protocol Number: MMC001 Start Date*: 2011-12-15
    Sponsor Name:Camden Provider Services
    Full Title: Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra© in combination with Truvada© for HIV post-exposure prophylaxis
    Medical condition: Prophylaxis and prevention of HIV Infection.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001193-34 Sponsor Protocol Number: STRIB-PEP Start Date*: 2014-07-16
    Sponsor Name:Fundació Clínic per a la recerca biomèdica
    Full Title: COMPARISON OF TWO ANTIRETROVIRAL ALTERNATIVE COMBINATIONS IN HIV-1 POST-EXPOSURE PROPHYLAXIS: TENOFOVIR+EMTRICITABINE (TRUVADA®) + LOPINAVIR/RITONAVIR (KALETRA®) VS TENOFOVIR+EMTRICITABINA+ COBICIS...
    Medical condition: Prophilaxis VIH infecction post accidental exposition (PPE)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10020160 HIV disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001223-14 Sponsor Protocol Number: VAJ00001 Start Date*: 2020-11-13
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Imovax® Rabies and VERORAB® Immunogenicity and Safety after One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Intradermal or Intramuscu...
    Medical condition: Rabies disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10069573 Rabies immunisation PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-001335-30 Sponsor Protocol Number: N0S103325 Start Date*: 2005-12-07
    Sponsor Name:GlaxoSmithKline R&D
    Full Title: A Multicentre, Two-Part, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy,Tolerability and Pharmacokinetics of the iNOS Inhibitor GW274150 Administered up...
    Medical condition: Prophylaxis of migraine headache
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058734 Migraine prophylaxis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) BE (Completed) FI (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-002829-29 Sponsor Protocol Number: ANRS174 Start Date*: 2019-12-12
    Sponsor Name:INSERM ANRS
    Full Title: Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex with Men using oral TDF/FTC for HIV Pre-Exposure Prophylaxis (PrEP)
    Medical condition: MSM with at least 6-month experience with PrEP (Pre-Exposure Prophylaxis)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003537-11 Sponsor Protocol Number: 19855 Start Date*: 2024-03-14
    Sponsor Name:Bayer Healthcare Company Limited
    Full Title: A Post Approval Commitment study to evaluate the efficacy, safety, and pharmacokinetics of KOVALTRY in Chinese children, adolescents/adults with severe hemophilia A.
    Medical condition: KOVALTRY, indicated for use in adults and children with hemophilia A (congenital Factor VIII deficiency) for: - Routine prophylaxis to reduce the frequency of bleeding episodes - On-demand treatmen...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10060612 Hemophilia A LLT
    20.0 10042613 - Surgical and medical procedures 10071818 Bleeding prophylaxis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-000305-13 Sponsor Protocol Number: RIVAROXDVT3002/BAY59-7939/17261 Start Date*: 2014-07-07
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER)
    Medical condition: Prevention of symptomatic venous thromboembolism (VTE) and VTE-related death posthospital discharge in high-risk, medically ill patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) HU (Completed) CZ (Completed) IT (Completed) ES (Completed) NL (Completed) LT (Completed) BG (Completed) GR (Completed) LV (Completed) AT (Completed) DE (Completed) GB (Completed) PT (Completed) SK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005564-21 Sponsor Protocol Number: SIRAVA Start Date*: 2021-12-28
    Sponsor Name:Leiden University Medical Center
    Full Title: Five-year boostability after single-visit single-dose intramuscular rabies pre-exposure prophylaxis.
    Medical condition: Healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10069589 Rabies immunization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004305-40 Sponsor Protocol Number: CSL222-3001 Start Date*: 2018-10-12
    Sponsor Name:CSL Behring LLC
    Full Title: Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene ...
    Medical condition: Hemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Ongoing) GB (GB - no longer in EU/EEA) IE (Restarted) NL (Ongoing) DE (Restarted) BE (Ongoing) SE (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000934-77 Sponsor Protocol Number: 4.0 Start Date*: 2018-05-11
    Sponsor Name:Medical University of Vienna
    Full Title: Target attainment of Cefazolin Continuous Infusion for Antibiotic Prophylaxis in patients undergoing CABG surgery
    Medical condition: Patients referred for CABG to the Department of Cardiac Surgery with planned isolated left mammary artery and vein/radial artery grafts preparation will be asked to participate in this trial.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003001-58 Sponsor Protocol Number: NN7088-4595 Start Date*: 2022-11-01
    Sponsor Name:Novo Nordisk A/S
    Full Title: A multi-centre, open-label trial evaluating efficacy, safety and pharmacokinetics of turoctocog alfa pegol (N8-GP) when used for treatment and prophylaxis of bleeding episodes in previously treated...
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-004719-28 Sponsor Protocol Number: D8850C00003 Start Date*: 2020-11-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-002069-39 Sponsor Protocol Number: MARAVI-PEP Start Date*: 2011-09-16
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Comparación de dos combinaciones de antirretrovirales en la Profilaxis Post-Exposición al VIH-1: TDF-FTC (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs TDF-FTC (Truvada ®) + Maraviroc (Celsentri ...
    Medical condition: El estudio se realizará en sujetos no infectados por el VIH-1 que acudan a urgencias tras una potencial exposición al VIH.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10052361 HIV post exposure prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004210-33 Sponsor Protocol Number: SIG-001-121 Start Date*: 2020-06-11
    Sponsor Name:Sigilon Therapeutics, Inc.
    Full Title: A Phase 1/2 Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of SIG-001 in Adult Patients with Severe or Moderately-Severe Haemophilia A Without Inhibitors
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018937 Haemophilia A LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-005216-28 Sponsor Protocol Number: VNK115640 Start Date*: 2012-04-05
    Sponsor Name:GlaxoSmithKline
    Full Title: A Multicenter, Randomized, Single-blind, Active-controlled, Parallel Group, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of a Single Intravenous (6 mg, 12 mg, 18 mg, 24 mg or 3...
    Medical condition: Post-operative nausea and vomiting (PONV)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10036285 Postoperative nausea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005275-24 Sponsor Protocol Number: TACPKPD Start Date*: 2016-03-18
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE
    Full Title: Conversion pharmacodynamic study in stable renal transplant patients receiving tacrolimus two times a day to a new formulation of tacrolimus - LCP Tacro - 1 time a day.
    Medical condition: REJECTION PROPHYLAXIS IN RENAL TRANSPLANT PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10050436 Prophylaxis against renal transplant rejection LLT
    18.1 10042613 - Surgical and medical procedures 10038533 Renal transplant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004707-40 Sponsor Protocol Number: RAB40 Start Date*: 2019-02-25
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Verorab® immunogenicity and safety after a one week, 4-site, intradermal (ID) post-exposure prophylaxis regimen (4-4-4-0-0) followed by a one visit, 4-site, ID booster at five years.
    Medical condition: Rabies
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002663-10 Sponsor Protocol Number: SSAT049 Start Date*: 2012-11-12
    Sponsor Name:St Stephen's AIDS Trust
    Full Title: A phase IV, open-label single-arm study investigating the pharmacokinetics and pharmacodynamics of the antiretroviral combination of rilpivirine and ritonavir-boosted darunavir in therapy-naive HIV...
    Medical condition: HIV-1
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002041-59 Sponsor Protocol Number: DP10018 Start Date*: 2015-09-11
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Randomised, double-blind, placebo-controlled study of APD421 (amisulpride for IV injection) as treatment of established post-operative nausea and vomiting, in patients who have had no prior prophyl...
    Medical condition: Post-operative nausea and vomiting
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022117 - Injury, poisoning and procedural complications 10066962 Procedural nausea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:45:39 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA